Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria

Background  Chronic spontaneous urticaria (CSU), a mast cell‐driven condition, is debilitating, common, and hard to treat. Miltefosine, a lipid raft modulator, can inhibit mast cell responses in vivo. Objective  To study the safety and efficacy of systemic miltefosine treatment in CSU patients resis...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of the European Academy of Dermatology and Venereology 2013-03, Vol.27 (3), p.e363-e369
Hauptverfasser:	Magerl, M., Rother, M., Bieber, T., Biedermann, T., Brasch, J., Dominicus, R., Hunzelmann, N., Jakob, T., Mahler, V., Popp, G., Schäkel, K., Schlingensiepen, R., Schmitt, J., Siebenhaar, F., Simon, J.C., Staubach, P., Wedi, B., Weidner, C., Maurer, M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Chronic Disease Double-Blind Method Histamine Antagonists - therapeutic use Humans Phosphorylcholine - adverse effects Phosphorylcholine - analogs & derivatives Phosphorylcholine - therapeutic use Placebos Urticaria - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!